Stephen Curtis

Stephen Curtis, Ph.D.

Investment Team

Cambridge Office

Dr. Stephen (Steve) Curtis oversees MPM’s investment collaboration with Dana-Farber Cancer Institute and brings to his role experience in early-stage, start-up creation and strategic deal structuring and negotiation in the biotech and pharmaceutical industries. He is also responsible for investment identification, due diligence and business development and supports MPM’s partnership with Gilead Sciences.

Prior to joining MPM, Steve was Senior Director of Business Development – Emerging Technology and Innovation for Eli Lilly and Company, out of Lilly’s external research hub in Cambridge, MA. In that role, he focused on Lilly’s strategic limited partnerships in top-tier venture funds, direct equity investments in selected biotechnology companies, “build-to-buy” investments and other “shared-risk” drug discovery and early development relationships. Prior to Lilly, Steve co-led the Bioscience Ventures group within 2M Companies, the Dallas-based family office of Morton H. Meyerson, focusing on Seed and Series A biotech investments and portfolio management. Before 2M, he worked at Reata Pharmaceuticals, entering through their Biotechnology Leadership Development program and ultimately running the Technology Evaluation and In-Licensing program. Steve also interned at Siemens Venture Capital in Boston while finishing his graduate studies.

Steve completed the competitive, two-year venture capital Kauffman Fellows training program. He earned his Ph.D. in Biological and Biomedical Sciences at Harvard Medical School and a dual B.S. degree, summa cum laude, in Molecular Biology and Applied Economics and Management from Cornell University.